Essais liés11clinical trials
VilleDetroitlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07198074

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
Biospecimen Collection Cancer Phase 3 NCT07097142 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study RECRUITING
Bevacizumab Cancer Phase 3 NCT07198074 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer RECRUITING
Biopsy Procedure SEP Phase 2 NCT02143414 Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia ACTIVE_NOT_RECRUITING
Biospecimen Collection Cancer Phase 3 NCT06058377 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer RECRUITING
Azacitidine Cancer Phase 2 NCT05554406 Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) RECRUITING
Acalabrutinib Cancer Phase 2 NCT04115631 A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma ACTIVE_NOT_RECRUITING
Biospecimen Collection Cancer Phase 3 NCT06337318 Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma RECRUITING
Biopsy Procedure Cancer Phase 1/2 NCT04172532 Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer RECRUITING
Biospecimen Collection Cancer Phase 3 NCT05675410 A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab RECRUITING
Biospecimen Collection Cancer Phase 3 NCT05256225 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma RECRUITING
Biospecimen Collection Lupus Phase 1 NCT03816345 Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO RECRUITING